Sotalol
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Sotalol
- Sotalol: From Cardiac Arrhythmia to Sick Sinus Syndrome 2, Autosomal Dominant
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence (Rank 1: Sick Sinus Syndrome 2, Autosomal Dominant)
- Literature Evidence (Rank 1: Sick Sinus Syndrome 2, Autosomal Dominant)
- Other Ranked Candidates in This Evidence Pack
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Sotalol: From Cardiac Arrhythmia to Sick Sinus Syndrome 2, Autosomal Dominant
One-Sentence Summary
Sotalol is a Class II/III antiarrhythmic (non-selective β-blocker combined with potassium-channel blockade), with an established clinical role in atrial fibrillation/flutter rhythm control and ventricular arrhythmias. TxGNN’s top-ranked prediction is Sick Sinus Syndrome 2, Autosomal Dominant, but this is not a credible repurposing signal — sotalol suppresses sinus node automaticity and is a known contraindication in sick sinus syndrome, so the high graph score most likely reflects proximity noise rather than a real therapeutic relationship. Of the 7 candidates in this evidence pack, none reach a robust evidence tier; the only one with any real supporting data is an indirect stroke-risk signal (via AF rhythm control), rated L3 / “Research Question”.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not extractable from India licensing data (0 registrations on file); per drug class and cited literature, sotalol’s established use is cardiac arrhythmia — atrial fibrillation/flutter rhythm control and ventricular arrhythmias |
| Predicted New Indication | Sick sinus syndrome 2, autosomal dominant — flagged as mechanistically implausible, see below |
| TxGNN Prediction Score | 99.76% (rank 4825 in global candidate pool) |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
It is not. Sotalol’s own mechanism argues against this prediction. As a non-selective β-blocker (Class II) with additional Class III potassium-channel blocking activity, sotalol reduces sinus node automaticity and heart rate. Sick sinus syndrome is a disorder of already impaired sinus node function — using a drug that further suppresses sinus automaticity in this population is a recognized contraindication, not a treatment rationale. The evidence pack’s own rationale field for this candidate states this explicitly: the prediction is “opposite to established clinical pharmacology” and represents “knowledge-graph proximity misjudgment, not a therapeutic association.”
The same conclusion applies to most of the lower-ranked candidates in this pack: Wildervanck syndrome, sarcoglycanopathy, macrocephaly-dysmorphic-facies-psychomotor-retardation syndrome, and the deprecated ontology term “obsolete susceptibility to ischemic stroke” all have zero supporting trials or literature, and no plausible mechanistic link to sotalol’s β-blocking/K⁺-channel-blocking pharmacology.
The one candidate with partial biological plausibility is stroke disorder (rank 4): sotalol is an established rhythm-control agent for atrial fibrillation, and AF is a major risk factor for ischemic stroke, so effective rhythm control could plausibly reduce downstream stroke risk. However, none of the supporting trials use stroke as a primary endpoint for sotalol specifically — they mostly compare ablation vs. antiarrhythmic drug strategies for AF, with sotalol appearing as one comparator/control arm among several. This is indirect, extrapolated evidence, not direct proof of a stroke-prevention indication.
Clinical Trial Evidence (Rank 1: Sick Sinus Syndrome 2, Autosomal Dominant)
Currently no related clinical trials registered.
Literature Evidence (Rank 1: Sick Sinus Syndrome 2, Autosomal Dominant)
Currently no related literature available.
Other Ranked Candidates in This Evidence Pack
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 1 | Sick sinus syndrome 2, autosomal dominant | 99.76% | L5 | Hold | Mechanistically contraindicated, likely graph artifact |
| 2 | Wildervanck syndrome | 99.65% | L5 | Hold | No known mechanistic link; zero evidence |
| 3 | Sarcoglycanopathy | 99.64% | L5 | Hold | Cardiac involvement is a downstream complication, not a treatment target; zero evidence |
| 4 | Stroke disorder | 99.44% | L3 | Research Question | Only candidate with real (indirect) supporting evidence — see below |
| 5 | Manic bipolar affective disorder | 99.43% | L4 | Hold | Literature describes a drug-safety risk (QT prolongation with antipsychotics), not efficacy |
| 6 | Macrocephaly, dysmorphic facies, and psychomotor retardation | 99.42% | L5 | Hold | No mechanistic link; zero evidence |
| 7 | Obsolete susceptibility to ischemic stroke | 99.23% | L5 | Hold | Deprecated ontology term; should be removed from candidate list |
Rank 4 — Stroke Disorder: Supporting Evidence (indirect, via AF rhythm control)
Clinical Trials
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00911508 | NA | Completed | 2,204 | CABANA trial: catheter ablation vs. rate/rhythm-control drug therapy (incl. sotalol) for AF; largest comparator trial in this set |
| NCT05279833 | N/A (SLR/NMA) | Completed | 87,810 | Systematic review/network meta-analysis comparing safety of dronedarone vs. sotalol directly in AF patients |
| NCT00007605 | Phase 3 | Completed | 706 | CSP #399: compares amiodarone and sotalol for maintaining sinus rhythm in AF; background notes ~75,000 AF-related strokes/year |
| NCT02145546 | Phase 4 | Unknown | 600 | Sotalol, amiodarone, propafenone effects on AF burden in sick sinus syndrome patients post-pacing (post-hoc AF, not primary SSS treatment) |
| NCT00523978 | Phase 3 | Completed | 245 | STOP AF: cryoablation vs. drug therapy (incl. sotalol) after failure of AAD in paroxysmal AF |
| NCT07405671 | Phase 4 | Not yet recruiting | 988 | Flecainide vs. standard rhythm-control drugs (sotalol/amiodarone) in AF with stable CAD |
| NCT05511389 | NA | Recruiting | 1,500 | Cardioversion shock-vector RCT for AF; disease-area overlap only |
| NCT03118518 | NA | Completed | 225 | Cryoballoon ablation vs. AAD-naive paroxysmal AF |
| NCT01447862 | Phase 4 | Completed | 101 | Vernakalant vs. ibutilide in recent-onset AF |
| NCT03737929 | NA | Recruiting | 228 | Hybrid ablation vs. conventional catheter ablation, persistent AF |
Literature
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37485722 | 2023 | RCT | Circ Arrhythm Electrophysiol | Dronedarone vs. sotalol head-to-head in AAD-naive veterans with AF; effectiveness/safety comparison |
| 1281807 | 1992 | RCT | Int J Cardiol | Sotalol efficacy/safety in complex ventricular arrhythmias (n=356), ~76% reduction in PVCs |
| 29954667 | 2019 | Cohort | Int J Cardiol | Sotalol efficacy and safety in adults with congenital heart disease and arrhythmia |
| 28496906 | 2013 | Cohort | J Atr Fibrillation | Real-world risk of CV events/stroke/CHF: dronedarone vs. amiodarone and other antiarrhythmics including sotalol |
| 38011245 | 2023 | Review | Circulation | Contemporary AF management in hypertrophic cardiomyopathy, including stroke risk stratification |
| 25430048 | 2014 | Review | BMJ Clin Evid | Acute-onset AF management; AF increases stroke and heart failure risk |
| 39077579 | 2023 | Review | Rev Cardiovasc Med | Managing AF during pregnancy, incl. antiarrhythmic risk-benefit |
| 11445058 | 2001 | Review | Curr Treat Options Cardiovasc Med | Atrial flutter treatment overview |
| 37777295 | 2023 | Guideline | Am J Cardiol | ACC/AHA/HRS and ESC guideline recommendations on AAD selection |
| 8346725 | 1993 | Study | Am J Cardiol | Oral sotalol hemodynamic effects in patients with ventricular arrhythmias and structural heart disease |
Rank 5 — Manic Bipolar Affective Disorder: Not an Efficacy Signal
The 3 cited references (PMID 39179332, 32124390, 10958269) describe cardiac safety risks — QT-prolongation/torsades risk when β-blockers like sotalol are combined with antipsychotics (e.g., risperidone), and a case report of symptomatic bradycardia during lithium therapy. This is a drug-safety caution, not evidence that sotalol treats bipolar disorder.
India Market Information
Sotalol currently has no registered license in India (0 registrations, market status: Not Marketed). No product-level dosage form or approved-indication data is available in this evidence pack.
Safety Considerations
- Drug Interactions: 288 documented interactions on file. Notable Major-severity interactions include Epinephrine, Clarithromycin, Picosulfuric acid, and Polyethylene glycol (3350 with electrolytes) — combined use warrants caution given sotalol’s QT-prolonging and bradycardic pharmacology. Several Moderate-level interactions with anticholinergic and antidiabetic agents (e.g., Atropine, Hyoscyamine, Canagliflozin, Dapagliflozin, Cimetidine) are also on file.
- Data Gap (Blocking): India label warnings and contraindications are not yet available for this drug (DG001), which currently blocks a formal S1 safety review.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (sick sinus syndrome) is mechanistically implausible and likely a knowledge-graph artifact rather than a genuine repurposing signal. No candidate in this evidence pack reaches a level of evidence sufficient to justify advancing past a research hypothesis, and the one partially-supported candidate (stroke, via AF rhythm control) relies only on indirect trial evidence with no dedicated stroke endpoint. A Blocking data gap on India label warnings/contraindications (DG001) also prevents formal safety screening at this stage.
To proceed, the following is needed:
- Resolve DG001 (India/TFDA label warnings & contraindications) before any S1 safety review
- Resolve DG002 (confirmed MOA from DrugBank) to formally support or refute mechanistic rationale
- If pursuing the stroke-risk angle: identify or commission trials/meta-analyses using stroke incidence as a primary or pre-specified endpoint for sotalol specifically, rather than relying on ablation-vs-drug comparator trials
- Re-evaluate or exclude the top-ranked candidate (sick sinus syndrome) as likely model noise before any further workflow stage
- Remove “obsolete susceptibility to ischemic stroke” (rank 7) from active candidate tracking — it is a deprecated ontology term
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.